MO698: Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-Covid-19 Period: a National Multicenter Case–Control Study from Turkey. (3rd May 2022)

• Record Type: Journal Article
• Authors: Ozturk, Savas; Gursu, Meltem; Arici, Mustafa; Sahin, İdris; Eren, Necmi; Yılmaz, Mürvet; Ozberk, Sumeyra; Karahisar Sirali, Semahat; Ural, Zeynep; Dursun, Belda; Yuksel, Enver; Uzun, Sami; Sipahi, Savas; Ahbap Dal, Elbis; Yazici, Halil; Altunoren, Orcun; Tunca, Onur; Ayar, Yavuz; Gok Oguz, Ebru; Yilmaz, Zulfikar; Kahvecioglu, Serdar; Asicioglu, Ebru; Oruc, Aysegul; Ataman, Rezzan; Aydin, Zeki; Huddam, Bulent; Esra Dolarslan, Murside; Azak, Alper; Bakirdogen, Serkan; Ugur Yalcin, Ahmet; Karadag, Serhat; Sena Ulu, Memnune; Gungor, Ozkan; Ari Bakir, Elif; Riza Odabas, Ali; Seyahi, Nurhan; Yildiz, Alaattin; Ateş, Kenan;
• Is Part Of: Nephrology dialysis transplantation. Volume 37(2022)Supplement 3
• Publication Date: 2022-05-03
• Subjects: Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfac078.035
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: BACKGROUND AND AIMS: There is not enough data on the post-COVID-19 (coronavirus disease 2019) period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data retrospectively obtained in the follow-up of PD patients after COVID-19 with a control PD group. METHOD: This study, supported by the Turkish Society of Nephrology, is a national multicenter retrospectively case–control study involving adult PD patients with confirmed COVID-19, using data collected from 21 April 2021 to 11 June 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but who did not have COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. RESULTS: A total of 223 patients (COVID-19 group: 113, control group: 110) from 28 centers were included. The duration of PD in both groups was similar [median (IQR):3.0 (1.88–6.0) years and 3.0 (2.0–5.6)], but the patient age of the COVID-19 group was lower than the control group [50 (IQR:40–57) years and 56 (IQR:46–64) years, P < 0.001]. PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on Day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at Day 90. Only one (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition and hypervolemia were significantly higher at Day 90 in the COVID-19 group. CONCLUSION: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 is not different from the control PD group. However, some of these patients continue to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.